CONMED Focuses on Innovation to Recover Market Share in Orthopedics

CONMED is leveraging innovation to counteract recent declines in market share within the orthopedic sector. In the second quarter of 2025, the company's orthopedic sales reached $140.7 million, marking a slight increase of 0.9% compared to the same period in 2024. For the first half of 2025, total orthopedic revenue amounted to $279 million, representing a 1.7% year-over-year growth. This year, CONMED has outlined three strategic priorities aimed at revitalizing its orthopedics division: stabilizing and expanding operational capacity, enhancing efficiency through consulting partnerships, and developing a robust, high-performance supply chain. Despite these efforts, the company has faced challenges in maintaining market share against competitors over recent quarters. "Our growth rate lags behind the overall market," admitted CEO Pat Beyer. "While our absolute numbers indicate a decline in market share, we remain committed to innovation. Our BioBrace platform, for example, continues to advance and is actively used in 52 different procedures, including rotator cuff repairs, ACL reconstructions, and Achilles and gluteus medius surgeries. The foot and ankle segment has also experience...